Member Info for Bladderman

Compared to those without mutation.

Patients are 5x more likely to survive at Day 28 according to clinical trial data

The compound is 5 x more likely to survive at day 28 from an N of 58.

...today announces it has identified, by genetic testing, an optimal subgroup of acute respiratory distress syndrome (ARDS) patients for Traumakine treatment (intravenous interferon beta-1a) who showed a substantial reduction in mortality during the INTEREST trial.

Can tell he's not a scientist lol

If you had 1000 ARDS patients, the treatment wcould be very effective in 300-350 caucasion population and 500 African. Huge lucrative market for such efficacious therapy

Should do very well Matt.

It's on 10:15 with game changing news...as it actually is very effective in sub populations

Can still treat a third of Caucasians for an unmet clinical need and nearly half the number of Africans. This company used to be worth £300M....not £25M

There is a medical need to fast track this product if it is showing very good efficacy in a sub population...

Work is spreading regarding the significance of this news and JV potential. Nice while it's still under a pound!

As far as AIM goes this is known in the field as a no brainer..

My account wontt let me move more money on App. How frustrating!

Very significant news for ARDS therapy...

Didn't they raise at £9 a share or similar before the diasterous news. Share on the ascendancy...

Look how cheap it is lol (£25M). Surely will reach £50M very near term

Wpuld not be surpised to see this back over £1.50 over the next few trading sessions as the market realises that the drug is still potentially very effective

Should see well over a pound today. This is a game changer. Meds will never be a one glove fits all approach. Always about the sub populations.

Look at the state of the SP. I remember buying this 0.95-1.4p around 4-5 years ago on first Wolfamite assay results. Those who bought at 3p have around 3% of their investment left. Not cool

Yep. A few dig trades changing hands. Let's see what December brings!